The development of pharmacological treatments for progressive multiple sclerosis (PMS) is an unmet need in current MS care. While to date a number of drugs that are highly effective in reducing magnetic resonance imaging (MRI) inflammatory activity and clinical relapse rate are available for relapsing-remitting MS (RRMS), there is a dearth of treatments for patients in the progressive phase of the disease. The recent approval of the monoclonal antibody ocrelizumab for the treatment of primary progressive MS (PPMS) by the Food and Drug Administration following a successful phase-3 trial, however, brings new hope for this underserved population. 1 The aim of this review is to evaluate the current challenges facing the design of clinical trials for PMS.
Introduction
The development of pharmacological treatments for progressive multiple sclerosis (PMS) is an unmet need in current MS care. While to date a number of drugs that are highly effective in reducing magnetic resonance imaging (MRI) inflammatory activity and clinical relapse rate are available for relapsing-remitting MS (RRMS), there is a dearth of treatments for patients in the progressive phase of the disease. The recent approval of the monoclonal antibody ocrelizumab for the treatment of primary progressive MS (PPMS) by the Food and Drug Administration following a successful phase-3 trial, however, brings new hope for this underserved population. 1 The aim of this review is to evaluate the current challenges facing the design of clinical trials for PMS.
As recently summarized by Ontaneda et al. 2 and reported in Table 1 , a relatively small, but steadily rising number of clinical trials have been conducted in PMS. These studies are highly heterogeneous regarding the characteristics of the target population and their outcome measures. Here, we argue that while safety and efficacy of candidate drugs are ultimately the key factors that can lead a clinical trial to success, flawed trial planning can be responsible for negative outcomes. The potential negative impact of inadequate trial design or wrong targets is far from unique to the PMS field. Inside neurology, for example, it is thought that flawed trial designs have significantly contributed to the recent streak of failures in the field of Alzheimer's disease pharmacological research. 3 We will briefly review the key issues in pharmacological clinical trial planning in PMS, that is, the characteristics of the enrolled population, the MRI and clinical outcome measures, and the trial statistical design.
Population selection
A key issue in clinical trial design is the choice of inclusion and exclusion criteria for patient enrollment. In PMS trials, the characteristics to take into account are represented by disease phenotype (PPMS vs SPMS), presence of inflammatory activity at baseline as assessed with MRI, disability levels, length and slope of the progressive phase before enrollment, and sex and age.
In SPMS, the impact of population baseline characteristics on clinical trial results has been clearly shown by the comparison of the European 4 and North American 5 studies on interferon beta-1b both terminated early at interim analysis, but efficacy and futility, respectively. 6 Indeed, while both studies were adequately powered, the European study included relatively younger subjects, with a more marked inflammatory activity and a shorter history of progression 6 and this study showed a positive effect. A similar effect of baseline inflammatory activity has also been shown in PPMS in the OLYMPUS trial, 7 where a positive effect of rituximab has been shown only in younger patients with MRI evidence of active inflammation and not on the whole PPMS population. The relative importance of inflammatory activity, however, needs to be evaluated in the light of the mechanism(s) of action of the tested drug, with compounds with a putative neuroprotective rather than anti-inflammatory effect often failing to modulate active inflammation in PMS subjects. 8 Conversely, drugs with significant anti-inflammatory effect-such as ocrelizumabhave been shown to positively impact disability progression also in PPMS subjects without detectable pathological gadolinium-enhancing lesions 1 but the treatment effects were diminished among those without baseline inflammatory activity.
Another key parameter is represented by the reference population progression rate, that is, the rate of progression among the subjects enrolled in the placebo arm. Indeed, a milder than predicted disability progression in the placebo arm was cited as one of the factors leading to futility in the early discontinuation of the glatiramer acetate PROMiSE trial in PPMS. 9 In support of this, it was reported that a slight positive treatment effect on disability progression was observed in enrolled males, which may be due to the higher baseline progression rate in this subgroup. 10 However, given the overall lack of effect, such subgroup explanations must also consider a counter-balancing negative effect in females.
Finally, paraclinical biomarkers could be used to guide patient selection to target those subjects more likely to respond to a specific treatment. For example, the presence of oligoclonal bands in the cerebrospinal fluid was an enrollment criterion for both the rituximab and ocrelizumab PPMS trials, and it is in line with their proposed action on antibody-producing cells. 1, 7 Outcome selection: phase-2 studies It can be argued that the successes of RRMS trials were in part due to the availability of a biomarker or surrogate marker in anti-inflammatory drug trials (i.e. contrast-enhancing lesions) that could be meaningfully linked to both the underlying disease pathology and the effect of the tested drug. To date, no such validated biomarker is available for PMS trials. This has led to a focus using MRI based mainly on the assessment of brain volume changes, as a proxy measure of degeneration. Compared to the inflammatory nature of contrast-enhancing lesions, brain volume loss lacks pathological specificity as it represents a final common pathway of multiple pathological processes including neuro-axonal loss, reduction of inflammatory infiltrates, and edema 11 and occurs to a lesser degree in normal aging.
Despite its lack of pathological specificity, the evaluation of brain atrophy presents some advantages from a clinical trial point of view, such as noninvasive healthy population normative data, ease of acquisition of volumetric MRI images, and availability of validated analysis pipelines. 12, 13 However, it is not totally established what measure of atrophy is most informative: whole-brain atrophy, white matter, or gray matter changes, or atrophy of specific regions (thalamus, corpus callosum, or cerebellum).
To be a useful marker for phase-2 studies, brain atrophy must be detectable over short periods of time (not longer than 1 year) and have demonstrated predictive validity. However, time lags between treatment and development of meaningful atrophy changes have been observed. 14 This could be due to processes started prior to the trial and which could be differently impacted by the specific mechanisms of action of different drugs. Indeed, in a single-center study of interferon beta-1b on PPMS, no treatment effect on brain volume was shown at the end of the 2-year treatment period 15 thus leading to treatment withdrawal; after 5 years from the end of the study, however, those subjects previously treated with interferon beta-1b showed less brain volume loss compared to placebo subjects. 16 Conversely, no apparent therapeutic lag was observed in the simvastatin trial as a similar rate of atrophy was found in the first and second years of the study. 8 The different results of these studies suggest that different mechanism of action may have a different temporal impact on brain volume. Sample sizes needed to demonstrate treatment benefit on whole-brain atrophy progression have been estimated and are similar to those required for phase-2 studies based on lesion counts. To show a 50% reduction in the accumulation of brain atrophy with 90% power, 69 subjects per arm are needed for a 1-year trial. 17 To improve the sensitivity to change of atrophy measures, it has been proposed to focus on individual brain structures such as the cervical spinal cord 18 and the cerebellum, 19 rather than on the whole brain, which presents with more marked volume changes over time in the PMS population. This approach, however, is also not without problems. First, different brain regions can present with different atrophy rates over time and among disease subtypes. In a cervical spinal cord study, 20 the sample size to show a 30% treatment effect using the cervical spinal cord was estimated at 157 subjects per treatment arm utilizing PPMS patients, but 1538 subjects per arm if an SPMS-only study population were enrolled. These results suggest that cervical cord area is more sensitive to change in PPMS than in SPMS. As for the cerebellum, the sample size estimation indicate feasible studies: the numbers of patients required to detect a 30% treatment difference has been estimated to be 81 per arm for cerebellar volume and 162 per arm for cerebellar cortex volume (90% power, type 1 error alpha = 0.05). 19 Atrophy measures are not the only possible choice of outcomes for phase-2 PMS trials. For example, assessment of caudate and brainstem integrity and architecture via MRI diffusion weighted measures have been shown to be the metrics most sensitive to change over 1 year in PMS in two independent datasets, 21 among a set of 58 possible candidates. Diffusion-based MRI parameters may be a reasonable outcome for PMS, given their ability to capture diffuse neuro-axonal loss in extra-lesional tissue and in gray matter (i.e. to probe key compartments for disability progression). 22 However, these measures may lack pathological specificity and the standardization of diffusion protocols between different scanners and sites is not a trivial challenge, thus reducing the appeal of this approach for multi-center studies at this time.
The sample size estimates for diffusion-based metrics have been reported and are highly variable depending on the specific metric (being lower for fractional anisotrophy than for mean diffusivity) and the area of the brain (being lower for the corpus callosum than the supratentorial brain). 23 Other possible non-MRI biomarkers include quantification of serum neurofilament light chains and of retinal nerve fiber layer thickness. 24, 25 However, more data regarding their changes over time in PMS and their sensitivity to pharmacological treatments are needed to assess their ability to replace the role of MRI as the primary outcomes of phase-2 studies. Nevertheless, the potential cost savings and reduced participant burden in future trials should encourage their inclusion as secondary outcomes in phase-2 clinical trials.
The reproducibility of a biomarker is a key factor to take into account during the trial design phase, more so for smaller phase-2 studies. Regarding imaging parameters, different position statement papers have been produced in recent years (see, for example, Vrenken et al. 26 ). While the evaluation of the recommendations for each imaging modality is beyond the scope of this paper, the overall approach includes the optimization of acquisition parameters, the use of automated methods to extract metrics of interests to reduce inter-operator variability, and the analysis pipeline validation on publicly available reference datasets.
Outcome selection: phase-3 studies
The choice of outcomes in phase-3 PMS studies is challenging, as regulatory agencies usually require, at this stage, evidence of an effect on clinically relevant or meaningful measures. To date, almost all clinical studies of PMS include Expanded Disability Status Scale (EDSS) assessment, which is a potentially inadequate measure in the setting of PMS clinical trials. Indeed, in PMS patients, EDSS is fairly insensitive to all but the most relevant changes in ambulation, which usually are difficult to observe in the majority of PMS patients included in clinical trials due to a plateau effect and the choices of walking assistance aids. This problem was recognized early in PMS trials, and many studies were designed to use not only the EDSS (and ambulation scores) but also other functional outcomes, such as hand dexterity. The inclusion of upper limb measures hand dexterity measures, for example, allowed the oral methotrexate study to show a positive treatment effect, which would have not reached statistical significance if only the EDSS was taken into account. 27 More recently, the Multiple Sclerosis Functional Composite (MSFC) was developed as complementary outcome to EDSS adding its ability to quantitatively probe not only ambulation but also cognition and hand dexterity. 28 The MSFC has been shown to be a more sensitive measure of treatment efficacy than the EDSS in PMS; 29 however, it is not widely accepted by regulatory agencies as a primary clinical outcome measure, as its reliance on somewhat arbitrary normative data 30 does not allow one to unequivocally identify cut-off scores for clinically meaningful change and in the PMS population, increased personto-person variability in the upper ranges often diminishes the power to detect differences. To overcome this lack of intuitive clinical meaning, different approaches have been proposed such as evaluating the score variation leading to hard outcomes (e.g. vocational status changes) 31 or quantifying the impact of clear-cut clinical events-such as relapses 32 -on test scores. The identification of clinically meaningful changes is not a trivial problem. Overly sensitive outcomes can show statistically significant effects which lack meaning, predictive validity, or insensitive outcomes showing differences only due to massive sample sizes, without real clinical benefits. Sustained changes in the EDSS have been combined with 20% changes in two of the components of the MSFC (i.e. 25-foot timed walk and 9-hole peg test) leading to a disconjugate clinical outcome: significant worsening or not. This by itself and in combination with MRI has been used in definitions of no evidence of disease activity (NEDA). NEDA is an outcome with face validity for a clinically meaningful outcome, but may be overly dependent on the frequency of MRI assessment and thus may not be comparable across trials.
Overall, the correlation between clinical measures and MRI metrics is often limited in PMS, and this is partly due to the aforementioned limitations of clinical outcomes, but also, to the lack of pathological specificity of the currently used MRI approaches. While the correlation between MRI and clinical outcomes can be improved, for example, using composite MRI metrics, 33 the so-called "clinico-radiological" paradox should not be considered too negatively in the setting of PMS phase-3 clinical trials. Indeed, as ideal MRI or clinical outcome markers for PMS are currently lacking, the partial divergence between MRI and clinical measure could be used to create combined measures that are able to more completely capture potential treatment effects. However, such approaches need additional longitudinal information to better understand how specific measures may be used to test specific therapeutic mechanisms of action.Regulators may be slow to accept such measures without further information.
Objective measures of disability are usefully complemented by quality of life and other patient-centered outcomes. While the construct of quality of life is not easy to probe, it allows the evaluation of a key objective of medical treatment, that is, improvement of subjective well-being. The correlation between MRI and disability metrics and patient-centered outcomes are often limited, indicating the need to include the latter in clinical trials to fully capture the impact of the disease and treatment on the patients (and the full potential of candidate treatments). 34 However, as primary outcomes, general or global quality-of-life measures are not specific to MS they may be difficult to interpret in terms of treatment effects. Nevertheless, patient-centered outcomes are increasingly required by regulatory agencies to show positive impacts of novel treatments on patients, even though they may not be acceptable as primary outcomes.
Clinical trial design
The last-but not least-ingredient to a successful clinical trial is represented by the design of the trial itself, that is, the number of treatment arms, the early termination or adaptation criteria, and the statistical analysis plan.
To tackle these challenges, an interesting approach is represented by reaching out to clinical trials experts in other fields of medicine, such as oncology. While many aspects of oncology trials are vastly different such as using well-defined outcomes, death or progression-free survival, some of the challenges faced in oncology are similar to PMS clinical researchers. These problems include the availability of a reasonable number of potentially effective drugs, a relatively narrow therapeutic window that reduces the size of the enrollment pool, and a feeling of urgency to reach clinically meaningful solutions.
To these aims, oncologists started to plan and execute novel clinical trial designs, including so-called adaptive trials and single trial networks. A successful example is represented by the systemic therapy for advancing or metastatic prostate cancer (STAMPEDE) trial. 35 In this trial format, different treatment choices are not pre-determined but are dynamically influenced by the collected data and evolving treatments grafted into the same trial network. 36 As an example is the adaptive randomization used in STAMPEDE.
In "classical" clinical trials, randomization criteria are fixed beforehand, while in adaptive randomization, the treatment allocation of each enrolling patient can be determined by the distribution of pre-determined covariates among the different treatment groups to reduce the impact of possible confounding factors or can be driven by the events happening in each arm. However, this can also lead to problems as was the case in the early phase-2 rituximab RRMS trial, where the treatment groups ended up severely unbalanced on the primary outcome variable at baseline.
Similar to the approach utilized by STAMPEDE, a unique aspect is that the number of treatment arms is not pre-determined, but some treatments can be stopped early if shown to present with a disadvantageous efficacy/safety ratio and new treatments added along the way. Adaptive trials, however, are not limited to oncology and indeed they have been already used in neurology in subjects with Alzheimer's disease 37 and via sample size reassessments in RRMS (as in the CONCERTO trial evaluating laquinimod vs placebo, where the sample size was increased due to the number of events that was lower than expected; https://clinicaltrials.gov/ct2/show/NCT01707992?ter m=concerto&rank=7). Adaptive trials, moreover, are also well suited to include biomarker-based stratification (which however can also be performed-albeit using only a priori hypothesis in non-adaptive clinical trials) of treatment arms. This approach uses a biological meaningful characteristic (such as, for example, for PMS, the presence of MRI evidence of active inflammation) to guide the allocation to specific treatment arms, thus potentially allowing the trial to maximize the therapeutic effect for at least a subgroup of subjects (or for more than one subgroup if drugs with different mechanisms of action are used). 38 Adaptive trials can also be based on statistical techniques called Bayesian methods. These methods are different from the standard frequentist approach which has the great virtue of an extreme rigor and strict adherence to the experiment, but can be less adaptable and/or flexible limiting innovation in the design and analysis of clinical trials. 39 Bayesian methods integrate the results of the study with previous and/or external evidence, having as a very useful consequence the ability to quantify what is going to happen in a trial from any point on (including from the start of the trial), given the currently available results, with a constant monitoring. 39 However, use of these tools assume comparability of the patients enrolling over time and some other specific statistical assumptions. Bayesian methods require intense statistical modeling and simulations in planning and may require larger sample sizes to adequately capture the posterior distribution of treatment parameter of interest. However, advances in computational techniques and the widespread availability of high-speed computers have facilitated the application of these methods. Their application for designing more flexible trials in PMS should be explored.
Summary
Here, we reviewed some key issues in clinical trial planning in PMS and argued that while good trial design cannot overcome the limitations of candidate drugs, poorly planned trials can lead to unnecessary negative results. Overall, based on the presented evidence, key issues in trial design and planning are represented by an adequate matching of the candidate drug with the specified inclusion and exclusion criteria; clinical, biomarker, or surrogate outcomes; and statistical analysis techniques. Progress has been made using techniques to date, but future progress may be enhanced by fully exploring some of the techniques and approaches discussed above.
